Drugs / PG-760564
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00791817 | Aug 2005 → Jan 2006 | — | Procter and Gamble | Completed | No outcome recorded |
| Phase 1 | NCT00791388 | Aug 2005 → Jan 2006 | — | Procter and Gamble | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT00369928 | Aug 2006 → Jan 2008 | rheumatoid arthritis | Procter and Gamble | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG 760564 | “using 200 mg oral dose of PG 760564” NCT00791817 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL3545398 ↗ |
| Route | Oral | “100 mg BID, of oral PG-760564” NCT00369928 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL3545398 ↗ |